Be Prepared to Dispense Alternatives to Usual COVID-19 Meds

Shortages of tocilizumab (Actemra) mean you'll see more orders for other COVID-19 treatments.

Tocilizumab has been the go-to add-on to steroids (dexamethasone, etc) for COVID-19. It's because this "IL-6 inhibitor" has the strongest evidence for reducing mortality.

But tocilizumab supplies are low. And it may need to be reserved for other uses where tocilizumab is the only treatment.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals